Check our MATCH-R collection
Special PDX models established from patients who proved demonstrated acquired resistance to last generation therapies !
Drive your future research now by clicking below !
Premium preclinical CRO offering innovative solutions for the development of new anticancer therapies
As a preclinical oncology CRO, XenTech believe in expertise, carry innovative values and creative solutions to facilitate and make emerge new efficient tools to fight cancer globally. We’re not in the size or numbers’ race but rather favor precisely targeted tools and services that will provide easier and faster solutions to the oncology research community and ultimately improve patients’ health.
With this spirit we are constantly evolving and prefer focusing on underserved niche (pediatric oncology), accurate models addressing nowadays needs in oncology research (MATCH-R line of PDX reflecting acquired resistance to newly approved or in clinical evaluation drugs) and capitalize on our historic expertise in Breast cancer for which we aim to be THE #1 Reference.Discover
XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)
Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !
XenTech will attend the World ADC London (Mar.- 13-16th)
Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !
XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)
Our Head of R&D Oliver Déas will be delighted to discuss with you as he'll be attending in person.